An Examination of Patient Experiences and the Need for Enhanced Communication in UK Fertility ServicesThe Human Fertilisation and Embryology Authority (HFEA) recently released its 2024 National Patient Survey, offering a comprehensive overview of patient experiences within the UK’s fertility treatment landscape. The survey, encompassing responses from 1,500 individuals, reveals that 73% of fertility patients expressed satisfaction with their most recent treatment. This marks the third consecutive survey where satisfaction levels have exceeded 70%, indicating a consistent trend over the past decade. Notably, patients in the North East of England reported the highest satisfaction rates at 86%, while those in Wales reported the lowest at 68%. 

Despite these positive overall figures, the survey highlights significant disparities among different demographic groups. Satisfaction levels among Asian and Black patients were notably lower, at 50% and 59% respectively. These groups also reported less satisfaction with the quality of information provided by clinics, with 66% of Asian and Black patients expressing contentment, compared to 78% overall. The HFEA suggests that these disparities may be linked to lower birth rates and reduced access to NHS-funded treatments within these communities. 

The survey also sheds light on the concerning prevalence of unproven add-on treatments in fertility care. Approximately 73% of patients reported using at least one additional test, treatment, or emerging technology during their fertility journey. Commonly utilized add-ons include acupuncture, supplements, and additional medications, many of which lack substantial evidence supporting their efficacy in enhancing fertility outcomes. These extras can be costly, with some treatments reaching up to £1,500. Alarmingly, only 52% of patients had the effectiveness of these add-ons explained to them, and a mere 37% were informed about potential risks. 

Julia Chain, Chair of the HFEA, expressed concern over these findings, emphasizing the need for clinics to provide clear and comprehensive information about the efficacy, costs, and risks associated with additional treatments. The HFEA’s Code of Practice mandates that clinics must offer patients a transparent understanding of any treatment add-on, including its likelihood of increasing the chance of a successful pregnancy. Despite ongoing efforts since 2017 to reduce the use of unproven extras, their prevalence remains high, underscoring the necessity for improved communication and patient education. 

The survey further revealed that NHS-funded patients are experiencing longer wait times before commencing treatment. Only 35% of these patients began treatment within a year of consulting their GP, compared to 53% of self-funded patients. This disparity highlights ongoing challenges in the provision of timely fertility care within the NHS framework. 

In response to these insights, the HFEA aims to address these disparities and enhance patient experiences by advocating for equitable access to fertility treatments, ensuring transparent communication regarding treatment options, and promoting the provision of evidence-based care. The findings from the 2024 National Patient Survey serve as a crucial tool in informing policy and guiding improvements within the UK’s fertility services.

Sources:

26 March 2025. HFEA

• Fertility patients' satisfaction with treatment is high but room for improvement remains, says HFEA

26 March 2025. HFEA

• National Patient Survey 2024

26 March 2025. BBC News

• Fertility patients sold unproven add-ons, HFEA says